

# The Contemporary Management of Type 2 Diabetes: Focus on the Evolving Role of GLP-1 Receptor Agonists

## Recorded Podcast #1

**Title: Case Discussion: Practical Considerations When Adding a GLP-1 RA to Background Glucose-Lowering Therapy to Improve Cardiovascular Outcomes**

### Selected References

American Diabetes Association. Standards of Medical Care in Diabetes – 2020. *Diabetes Care*. 2020;43(suppl 1):S1-S212.

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2020;63:221-228.

Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonists added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis. *Diabetes Metab Rev*. 2019;35:e3082.

Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2020;76(9):1117-1145.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018;41:2669-2701.

de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. *Kidney Int*. 2020;98(4):839-848.

Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. *Lancet*. 2019;394:121-130.

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-322.

Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834-1844.